Golden
Aclaris Therapeutics

Aclaris Therapeutics

Aclaris Therapeutics is a company developing treatments for dermatology and immunology.

All edits by  Dawson Sewell 

Edits on 29 Mar 2019
Dawson Sewell
Dawson Sewell edited on 29 Mar 2019 6:46 pm
Edits made to:
Infobox (+5/-1 properties)
Timeline (+3 events) (+762 characters)
Article (+844/-26 characters)
Categories (+1/-2 topics)
Related Topics (+1 topics)

Article

Aclaris Therapeutics is a publicly held biopharmaceutical company basedheadquartered in that Waynewas founded in 2012 by Christopher Powala, , PennsylvaniaFrank Ruffo, Neal Walker, Stuart D. Shanler. itIt focuses on identifying, developing, and commercializing therapies to address unmet needs in dermatology, including medical, aesthetic, and immunology. The company explores therapies for market segments with no FDA-approved medications.



Products

...



Funding

Series A

On October 24, 2012 Aclaris Therapeutics completed their series A funding round with $21 million in funding from Vivo Capital (lead investor), F-Prime Capital Partners (lead investor), and Sofinnova Ventures. 

Series B

On October 2, 2014 Aclaris Therapeutics completed their series B funding round with $21million in funding from Vivo Capital, F-Prime Capital Partners, and Sofinnova Ventures.

Series C

On September 9, 2015 Aclaris Therapeutics completed their series C funding round with $40 million in funding from RA Capital Management (lead investor), Vivo Capital, Sofinnova Ventures, Rock Springs Capital, Mossrock Capital, F-Prime Capital Partners, Cormorant Asset Management, and Aperture Venture Partners. 

Infobox

Categories

Related Topics

Timeline

September 9, 2015

Series C funding round

On September 9, 2015 Aclaris Therapeutics completed their series C funding round with $40 million in funding from RA Capital Management (lead investor), Vivo Capital, Sofinnova Ventures, Rock Springs Capital, Mossrock Capital, F-Prime Capital Partners, Cormorant Asset Management, and Aperture Venture Partners. 

October 2, 2014

Series B funding round

On October 2, 2014 Aclaris Therapeutics completed their series B funding round with $21million in funding from Vivo Capital, F-Prime Capital Partners, and Sofinnova Ventures.

October 24, 2012

Series A funding round

On October 24, 2012 Aclaris Therapeutics completed their series A funding round with $21 million in funding from Vivo Capital (lead investor), F-Prime Capital Partners (lead investor), and Sofinnova Ventures. 

Edits on 11 Jan 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 11 Jan 2019 3:47 pm
Edits made to:
Article (+19/-19 characters)

Article

Aclaris Therapeutics is a publicly held biopharmaceutical company based in Wayne, PennsylvaniaWayne, Pennsylvania. it focuses on identifying, developing, and commercializing therapies to address unmet needs in dermatology, including medical, aesthetic, and immunology. The company explores therapies for market segments with no FDA-approved medications.

No more activity to show.